<p>Aprea Therapeutics Inc. has received a deficiency letter from the Nasdaq Listing Qualifications Department, notifying the company that its common stock has traded below the minimum required bid price of $1.00 per share for 30 consecutive business days. This puts Aprea at risk of being delisted from the Nasdaq Capital Market if it does not regain compliance within a 180-day period ending July 22, 2026. The company may seek a second compliance period or appeal a delisting determination if necessary. Aprea Therapeutics is considering actions such as a reverse stock split to address the issue, but there is no assurance it will regain compliance. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-006267), on January 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

SBIO

APRE

<p>Aprea Therapeutics Inc. is at risk of being delisted from the Nasdaq due to its common stock trading below the minimum bid price of $1.00 for 30 consecutive business days. The company has 180 days to regain compliance, ending July 22, 2026. Aprea may consider actions like a reverse stock split but cannot guarantee compliance will be achieved.</p>

Aprea Therapeutics Faces Nasdaq Delisting Risk Over Minimum Bid Price